多替阿巴拉米片在中国上市了吗？

A clinical application was submitted in China in 2015; it applied for import on January 20, 2017, and was granted priority review status; on August 1, 2017, the State Food and Drug Administration (CFDA) approved the entry of dolutea, a new compound preparation for the treatment of AIDS, into China. On January 20, 2018, GlaxoSmithKline China (GSK China) announced that its single-tablet compound preparation dolutea palamid tablets were officially launched in mainland China. This is the best-selling AIDS drug in the world in the past five years, and it is also an important part of GSK China in the field of AIDS in recent years. Since its approval for launch in 2014, the sales volume of Dolutegra abalami tablets has increased by leaps and bounds. In 2016, it ranked first in the global AIDS drug rankings, becoming GSK's best-performing business segment. Regarding pricing, Dolutegra abalami tablets are currently priced at $2,880/month in the Chinese market. In an interview with a reporter from E Drug Manager, Xu Ding, vice president of government affairs and communications at GSK, said: The price of Dolutea Paramid Tablets in China is the lowest in neighboring countries and regions. Next, GSK will actively coordinate and communicate with relevant departments to promote Dolutegra Abalamid Tablets to enter China's free AIDS drug list as soon as possible, benefiting more patient groups. 

There are currently two mainstream directions in the global treatment of AIDS. One follows the European and American guidelines, and the other follows the World Health Organization guidelines (which are guidelines formulated by the WHO based on various factors such as economy, resources, population income, etc. in underdeveloped areas). Currently, in the field of global AIDS treatment, DTG drugs are the only first-line drugs recommended by four guidelines (including IAS-USA, DHHS, EACS, and WHO). Since 1999, GSK has been approved for a total of eight HIV treatment drugs in China, and currently three products are on the national free catalog. The Dolutegra abalami tablets launched this time are China's first complete single-tablet three-in-one preparation with DTG as the core, filling the gap in single-piece compound preparations. GSK has previously had a DTG drug on the market, with the trade name Tevicay. It was launched in the United States in 2013, but it needs to be used in combination with other drugs. It is a complete single-tablet three-in-one preparation with DTG as the core, one pill at a time, once a day, without considering factors such as food, environment, location, etc. AIDS is generally recognized as a chronic disease. For chronic diseases, patient compliance is particularly important. One pill once a day reduces the frequency and dosage of medication and significantly enhances patient compliance. In the past, disease control focused more on the front-end, but now more and more attention is paid to the back-end. How patients use drugs and how to use them rationally also saves medical resources.